- Home
- ENFN vs SEPN Comparison
ENFN vs SEPN Comparison
Compare ENFN & SEPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENFN
- SEPN
- Stock Information
- Founded
- ENFN 1998
- SEPN 2022
- Country
- ENFN United States
- SEPN United States
- Employees
- ENFN N/A
- SEPN N/A
- Industry
- ENFN Computer Software: Prepackaged Software
- SEPN
- Sector
- ENFN Technology
- SEPN
- Exchange
- ENFN Nasdaq
- SEPN NYSE
- Market Cap
- ENFN 1.0B
- SEPN 1.0B
- IPO Year
- ENFN 2021
- SEPN 2024
- Fundamental
- Price
- ENFN $11.07
- SEPN $16.89
- Analyst Decision
- ENFN Hold
- SEPN Strong Buy
- Analyst Count
- ENFN 6
- SEPN 4
- Target Price
- ENFN $10.10
- SEPN $43.67
- AVG Volume (30 Days)
- ENFN 1.1M
- SEPN 432.4K
- Earning Date
- ENFN 03-11-2025
- SEPN 02-15-2025
- Dividend Yield
- ENFN N/A
- SEPN N/A
- EPS Growth
- ENFN N/A
- SEPN N/A
- EPS
- ENFN 0.03
- SEPN N/A
- Revenue
- ENFN $195,159,000.00
- SEPN $981,000.00
- Revenue This Year
- ENFN $18.88
- SEPN $406.62
- Revenue Next Year
- ENFN $17.75
- SEPN N/A
- P/E Ratio
- ENFN $523.34
- SEPN N/A
- Revenue Growth
- ENFN 15.78
- SEPN N/A
- 52 Week Low
- ENFN $7.52
- SEPN $15.86
- 52 Week High
- ENFN $11.38
- SEPN $28.99
- Technical
- Relative Strength Index (RSI)
- ENFN 60.80
- SEPN N/A
- Support Level
- ENFN $9.87
- SEPN N/A
- Resistance Level
- ENFN $10.40
- SEPN N/A
- Average True Range (ATR)
- ENFN 0.39
- SEPN 0.00
- MACD
- ENFN 0.06
- SEPN 0.00
- Stochastic Oscillator
- ENFN 96.09
- SEPN 0.00
About ENFN Enfusion Inc.
Enfusion Inc is a software-as-a-service (SaaS) provider focused on transforming the investment management industry. Its solutions are designed to eliminate technology and information barriers, empowering investment managers to make and execute an informed investment decisions in real-time. It simplifies investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset resulting in a single source of truth. It generates maximum revenue from Americas, followed by Asia Pacific and Europe, Middle East, and Africa.
About SEPN SEPTERNA INC
Septerna Inc is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by a proprietary Native Complex Platform. Its industrial-scale platform aims to unlock the full potential of GPCR therapies. The group discovery and development of a pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic disease. Its pipeline includes SEP-786 (PTH1R), SEP-631 (MRGPRX2), TSHR, and GLP-1R, GIPR, GCGR.